-
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus.
Syngelaki A, Kotecha R, Pastides A, Wright A, Nicolaides KH.
Metabolism 2015;64:1485-9. pdf -
Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Wright D, Silva M, Papadopoulos S, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:42-50. pdf -
Serum free b-human chorionic gonadotropin in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Wright D, Papadopoulos S, Silva M, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:51-9. pdf -
Serum alpha-fetoprotein in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Bredaki FE, Sciorio C, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:34-41. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Kagan KO, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:42-7. pdf -
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:118-26. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
First trimester maternal serum free ß-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
Savvidou M, Syngelaki A, Muhaisen M, Emelyanenko E, Nicolaides KH.
BJOG 2012;119:410-6. -
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705. -
First-trimester screening for neural tube defects using alpha-fetoprotein.
Bredaki FE, Poon LC, Birdir C, Escalante D, Nicolaides KH.
Fetal Diagn Ther 2012;31:109-14. -
Temporal effect of Afro-Caribbean race on serum pregnancy-associated plasma protein-a at 9-13 weeks' gestation in screening for aneuploidies.
Ball S, Wright D, Sodre D, Lachmann R, Nicolaides KH.
Fetal Diagn Ther 2012;31:162-9. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
First trimester maternal serum AFP and total hCG in aneuploidies other than trisomy 21.
Spencer K, Heath V, Flack N, Ong C, Nicolaides KH.
Prenat Diagn 2000;20:635-9.